Twist Bioscience Corporation (TWST)

Order flow on TWST suggests systematic accumulation by long-only institutional accounts during yesterday's dip.

On our desk, we are viewing the recent 200% stock surge as heavily driven by AI narrative momentum and potential short squeeze dynamics rather than clean operating fundamentals. While the raised fiscal 2026 revenue guidance to $456–$457 million is encouraging, the disconnect between a $9.5bn valuation and lingering SGandA losses leaves us neutral. We need to see concrete delivery on the targeted Q4 adjusted EBITDA breakeven before committing fresh capital.

In our laboratory research protocol evaluations, the core value proposition is the convergence of computational biology and precision DNA synthesis. Management highlighted that AI is rapidly becoming the primary screening tool for large pharma and biotech, shifting RandD workflows toward iterative design-build-test-learn cycles. The 39% growth in DNA Synthesis and Protein Solutions points to real secular adoption of these high-throughput synthesis tools.

Watching the 50-day moving average and options flow, max pain for the 2026-07-17 expiration sits around 87.50 with notable put open interest at the 57.50 strike against calls at the 100 strike. The sentiment reading remains balanced at a neutral 43 comfort level. Investors are heavily weighing the fundamental top-line expansion against the dilution overhang created by the $200 million at-the-market stock sale program filed via TD Securities.

From a risk management standpoint, we are monitoring the interplay between surging NGS Applications growth (up 12%) and the broader life sciences sector rotation. The recent 8.9% single-day pullback underscores how sensitive the stock is to any perceived dilution risk or insider distribution after sharp rallies. We are utilizing multi-leg option spreads to protect against downside volatility while maintaining exposure to AI therapeutic catalysts.

As a hedge fund portfolio manager, I am carefully tracking the recent insider sale filings alongside the $200 million ATM facility. Even though Q3 revenue topped consensus at $118.4 million (up 23% year over year) and major firms like TD Cowen, Piper Sandler, and Baird boosted price targets to $115, the widening EPS loss of $0.56 shows that operational scale has not yet translated into bottom-line safety.